Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
0.7988
-0.0082 (-1.02%)
Nov 20, 2025, 9:26 AM EST - Market open
Xilio Therapeutics Employees
Xilio Therapeutics had 64 employees as of December 31, 2024. The number of employees decreased by 9 or -12.33% compared to the previous year.
Employees
64
Change (1Y)
-9
Growth (1Y)
-12.33%
Revenue / Employee
$496,938
Profits / Employee
-$913,891
Market Cap
41.94M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 64 | -9 | -12.33% |
| Dec 31, 2023 | 73 | -16 | -17.98% |
| Dec 31, 2022 | 89 | 15 | 20.27% |
| Dec 31, 2021 | 74 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
XLO News
- 7 days ago - Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results - GlobeNewsWire
- 9 days ago - Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC Transcript - Seeking Alpha
- 13 days ago - Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting - GlobeNewsWire
- 13 days ago - Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting - GlobeNewsWire
- 16 days ago - Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 21 days ago - Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting - GlobeNewsWire
- 6 weeks ago - Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting - GlobeNewsWire
- 2 months ago - Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead - GlobeNewsWire